Paper42972049PubMed
A multi-institutional investigation of psilocybin's effects on mouse behavior.
Lu OD and 29 others. Nat Neurosci, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A multi-institutional investigation of psilocybin's effects on mouse behavior. Papers, record 42972049. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42972049
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A multi-institutional investigation of psilocybin's effects on mouse behavior.
- Journal
- Nat Neurosci
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-02
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P50 DA042012 | U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) | P50DA042012 | PubMed | NIH RePORTER | |
| K99 DA056573 | U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) | K99DA056573 | PubMed | NIH RePORTER | |
| P50 DA042012 | U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) | P50DA042012 | PubMed | NIH RePORTER | |
| K08 DA055157 | U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) | K08DA055157 | PubMed | NIH RePORTER | |
| K12GM081266 | U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) | K12GM081266 | PubMed | NIH RePORTER |
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,210,031 | Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. | Lancet Psychiatry | 2016 | https://conductscience.org/library/papers/27210031 | PubMed |
| 2 | 37,651,119 | Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. | JAMA | 2023 | https://conductscience.org/library/papers/37651119 | PubMed |
| 3 | 36,322,843 | Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36322843 | PubMed |
| 4 | 27,909,165 | Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. | J Psychopharmacol | 2016 | https://conductscience.org/library/papers/27909165 | PubMed |
| 5 | 27,909,164 | Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. | J Psychopharmacol | 2016 | https://conductscience.org/library/papers/27909164 | PubMed |
| 6 | 25,213,996 | Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. | J Psychopharmacol | 2014 | https://conductscience.org/library/papers/25213996 | PubMed |
| 7 | 25,586,396 | Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. | J Psychopharmacol | 2015 | https://conductscience.org/library/papers/25586396 | PubMed |
| 8 | 33,972,795 | MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. | Nat Med | 2021 | https://conductscience.org/library/papers/33972795 | PubMed |
| 9 | 37,709,999 | MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37709999 | PubMed |
| 10 | 40,906,494 | Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. | JAMA | 2025 | https://conductscience.org/library/papers/40906494 | PubMed |
| 11 | 24,594,678 | Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. | J Nerv Ment Dis | 2014 | https://conductscience.org/library/papers/24594678 | PubMed |
| 12 | 38,182,784 | Magnesium-ibogaine therapy in veterans with traumatic brain injuries. | Nat Med | 2024 | https://conductscience.org/library/papers/38182784 | PubMed |
| 13 | 28,402,682 | Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. | Am J Drug Alcohol Abuse | 2018 | https://conductscience.org/library/papers/28402682 | PubMed |
| 14 | 37,734,158 | Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. | Am J Drug Alcohol Abuse | 2023 | https://conductscience.org/library/papers/37734158 | PubMed |
| 15 | 33,852,780 | Trial of Psilocybin versus Escitalopram for Depression. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33852780 | PubMed |
| 16 | 27,568,263 | Psilocybin: panacea or placebo? | Lancet Psychiatry | 2016 | https://conductscience.org/library/papers/27568263 | PubMed |
| 17 | 37,588,757 | Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice. | ACS Pharmacol Transl Sci | 2023 | https://conductscience.org/library/papers/37588757 | PubMed |
| 18 | 33,850,049 | Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/33850049 | PubMed |
| 19 | 37,874,338 | Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/37874338 | PubMed |
| 20 | 31,106,729 | Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. | Acta Neuropsychiatr | 2019 | https://conductscience.org/library/papers/31106729 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42972049
GET https://conductscience.org/api/papers/v1/42972049/authors?page=2